Aeterna, Keryx end perifosine licence pact; Aeterna to continue PhIII multiple myeloma trial
This article was originally published in Scrip
Executive Summary
Aeterna Zentaris has regained North American rights to its novel oral anticancer Akt inhibitor, perifosine – a Phase III-stage compound – from Keryx Biopharmaceuticals, for all potential indications.